Glaukos has completed patient enrollment in an FDA investigational device exemption trial for the iStent infinite trabecular micro-bypass system.
The iStent infinite, designed to reduce elevated IOP in refractory glaucoma patients, consists of three heparin-coated titanium stents that are injected around Schlemm’s canal to restore the physiological outflow of the aqueous humor, according to a press release. It is inserted during a stand-alone procedure.
The prospective, unmasked, multicenter, single-arm clinical trial includes patients with previous unsuccessful incisional glaucoma
Uncategorized